NVCR – novocure limited - ordinary shares (US:NASDAQ)

News

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]
Novocure to Participate in 2026 Leerink Global Healthcare Conference
NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
NovoCure: Q4 Earnings Snapshot [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com